“Safety and Immunogenicity of VRC Multiclade HIV-1 Adenoviral Vector Vaccine Alone or with VRC Multiclade HIV-1 DNA Plasmid Vaccine in the African Adults”, in AIDS Vaccine 2007 Conference, Seattle, WA, 2007.,
“Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials”, PLoS ONE, vol. 3, p. e2043, 2008.,
“A Cross-Sectional Study in Eastern and Southern Africa to Characterize Laboratory Reference Intervals in Healthy Adults for HIV Prevention Trials”, in AIDS Vaccine 2008 Conference, Cape Town, South Africa, 2008.
“Safety and Immunogenicity Study of Multiclade HIV-1 Adeno-Viral Vector Vaccine Alone or as Boost Following a Multiclade HIV-1 DNA Vaccine in Africa”, PLoS ONE, vol. 5, p. e12873, 2010.,
“Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of Human Immunodeficiency Virus-1 Vaccine Candidates”, J Infect Dis, vol. 201, pp. 720-729, 2010.,
“Assessment of Viral Inhibition Activity in Low Seroprevalent Adenovirus-35 Vectored HIV Vaccines +/- Adjuvanted Protein or Electroporated DNA”, in HIV Research for Prevention 2014: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Cape Town, SA, 2014.,
“Clinical Safety and Immunogenicity of Two HIV Vaccines SeV-G(NP) and Ad35-GRIN in HIV-uninfected, Healthy Adult Volunteers”, in HIVR4P (HIV Research for Prevention), Cape Town, South Africa, 2014.,
“Major Negative Social Impacts are Rare in Phase 1 HIV Vaccine Trials in Africa”, in HIV Research for Prevention 2014: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P), Cape Town, SA, 2014.,